| Literature DB >> 36235013 |
Fatima Zahra Kamal1, Radu Lefter2, Cosmin-Teodor Mihai3, Hanane Farah1, Alin Ciobica4, Ahmad Ali5, Iulian Radu6, Ioannis Mavroudis7, Abdellah Ech-Chahad1.
Abstract
Taraxacum officinale (TO) has been historically used for medicinal purposes due to its biological activity against specific disorders. To investigate the antioxidant and the antiproliferativepotential of TO essential oil in vitro and in vivo, the chemical composition of the essential oil was analyzed by GC-MS. The in vivo antioxidant capacity was assessed on liver and kidney homogenate samples from mice subjected to acetaminophen-induced oxidative stress and treated with TO essential oil (600 and 12,000 mg/kg BW) for 14 days. The in vitro scavenging activity was assayed using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) and the reducing power methods. The cytotoxic effects against the HeLa cancer cell line were analyzed. The GC-MS analysis showed the presence of 34 compounds, 8 of which were identified as major constituents. The TO essential oil protected mice's liver and kidneys from acetaminophen-induced oxidative stress by enhancing antioxidant enzymes (catalase, superoxide dismutase, and glutathione) and lowering malondialdehyde levels. In vitro, the TO essential oil demonstrated low scavenging activity against DPPH (IC50 = 2.00 ± 0.05 mg/mL) and modest reducing power (EC50 = 0.963 ± 0.006 mg/mL). The growth of the HeLa cells was also reduced by the TO essential oil with an inhibition rate of 83.58% at 95 µg/mL. Current results reveal significant antioxidant and antiproliferative effects in a dose-dependent manner and suggest that Taraxacum officinale essential oil could be useful in formulations for cancer therapy.Entities:
Keywords: GC-MS; Taraxacum officinale; antioxidant activity; antiproliferative activity; cervical cancer (HeLa)
Mesh:
Substances:
Year: 2022 PMID: 36235013 PMCID: PMC9572089 DOI: 10.3390/molecules27196477
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Chemical composition of Taraxacum officinale essential oil.
| Name | a RI | b RI | % Area |
|---|---|---|---|
| Pentadecanoic acid | 1762 | 1777 | 2.28 |
| Tetradecanoic acid | 1774 | 1774 | 0.99 |
| 1987 | 1980 | 26.11 | |
| Thunbergol | 2051 | 2047 | 0.66 |
| Heptadecanoic acid | 2081 | 2080 | 0.81 |
| Heptadecanolide | 2094 | 2051 | 0.95 |
| 9,12-Octadecadienoic acid | 2105 | 2152 | 34.19 |
| n-Nonadecanol-1 | 2157 | 2153 | 1.36 |
| Octadecanoic acid | 2205 | 2165 | 1.11 |
| Linoelaidic acid | 2206 | - | 2.57 |
a RI: retention index measured relative to n-alkanes (C6–C30) on the non-polar 123 DB11 column. b Linear retention index taken from the NIST 05 library.
Figure 1Percentage inhibition of DPPH by different concentrations of Taraxacum officinale essential oil and the standard BHT. Results are expressed as means ± SD of three parallel measurements p < 0.01. BHT: butylated hydroxytoluene; EO: essential oil.
Pearson’s correlation coefficients between phenolic content and DPPH radical scavenging activity (IC50) of Taraxacum officinale essential oil.
| Correlation Pearson r | Phenolic Content | DPPH |
|---|---|---|
|
| 1 | 0.966 |
|
| 0.966 | 1 |
Reducing ability and EC50 values of Taraxacum officinale essential oil and ascorbic acid at different concentrations.
| Concentration (μg/mL) | Ascorbic Acid | EO |
|---|---|---|
| 1000 | 1.52 ± 0.005 | 0.64 ± 0.003 * |
| 800 | 1.21 ± 0.01 | 0.55 ± 0.04 * |
| 600 | 0.95 ± 0.03 | 0.48 ± 0.03 * |
| 400 | 0.71 ± 0.01 | 0.42 ± 0.05 * |
| 200 | 0.43 ± 0.01 | 0.34 ± 0.04 * |
| 0 | 0 | 0 |
| EC50 (mg/mL) | 0.034 ± 0.28 | 0.963 ± 0.006 |
Values are expressed as mean ± SD, n = 3, * p < 0.05 vs. standard. AA: ascorbic acid; EO: essential oil.
Body weight of mice during the treatment period.
| Treatments | Mean Body Weight in Grams ± SD | |
|---|---|---|
| Day 0 | Day 14 | |
| C | 29.39 ± 0.29 | 29.58 ± 0.24 |
| CMC | 30.48 ± 0.31 | 30.71 ± 0.30 |
| APAP | 32.54 ± 0.43 | 29.78 ± 0.65 * |
| AA | 27.47 ± 0.28 | 27.92 ± 0.72 |
| 30.24 ± 0.22 | 31.8 ± 0.71 | |
| 23.39 ± 0.27 | 23.81 ± 0.25 | |
C: normal control; CMC: vehicle–carboxymethylcellulose group 0.1%; APAP: acetaminophen-treated toxic control 400 mg/kg body weight (ip); TO 1: Taraxacum officinale essential oil 600 mg/kg body weight; TO 2: Taraxacum officinale essential oil 1200 mg/kg body weight; AA: ascorbic acid 200 mg/kg body weight. All data are means ± S.D. (n = 5/group), * p < 0.05 APAP at day 0 vs. APAP at day 14.
Relative organ weight to body weight of Swiss albino mice receiving Taraxacum officinale essential oil for 14 days.
| Groups/Organs | Relative Weight of Liver and Kidney (g/100 g) | |
|---|---|---|
| Liver | Kidneys | |
| C | 5.26 ± 0.26 | 1.37 ± 0.11 |
| CMC | 5.05 ± 0.11 | 1.36 ± 0.17 |
| APAP | 3.88 ± 0.13 *** | 1.04 ± 0.14 ** |
| AA | 4.66 ± 0.16 **; ### | 1.24 ± 0.08 *; # |
| 4.35 ± 0.55 ****, ### | 1.20 ± 0.13 *; # | |
| 4.61 ± 0.07 ***; ### | 1.22 ± 0.09 *; # | |
All values are expressed as means ± SD. C: normal control; CMC: vehicle–carboxymethylcellulose group 0.1%; APAP: acetaminophen-treated toxic control 400 mg/kg body weight (ip); TO 1: Taraxacum officinale essential oil 600 mg/kg body weight; TO 2: Taraxacum officinale essential oil 1200 mg/kg body weight; AA: ascorbic acid 200 mg/kg body weight (significant differences from normal control group * p < 0.05; ** p < 0.01; *** p < 0.001; and **** p < 0.001 significant differences from toxic control group # p < 0.05; ### p < 0.001).
Figure 2Effect of Taraxacum officinale essential oil on antioxidant enzymes and MDA levels against acetaminophen-induced liver injury in mice. Values are expressed as means ± SD (n = 5), * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 vs. the normal control group and # p < 0.05; ## p < 0.01; ### p < 0.001; #### p < 0.0001 vs. the toxic control group. (A) Effect of Taraxacum officinale EO on SOD level in liver and kidney of APAP-treated mice; (B) effect of Taraxacum officinale EO on GSH level in liver and kidney of APAP-treated mice; (C) effect of Taraxacum officinale EO on CAT level in liver and kidney of APAP-treated mice; (D) effect of Taraxacum officinale EO on MDA level in liver and kidney of APAP-treated mice. SOD: superoxide dismutase; GSH: reduced glutathione; CAT: catalase; MDA: malondialdehyde; AA: ascorbic acid; CMC: sodium carboxymethylcellulose; APAP: acetaminophen; TO 1: Taraxacum officinale essential oil 600 mg/kg body weight; TO 2: Taraxacum officinale essential oil 1200 mg/kg body weight.
Figure 3Effect of Taraxacum officinale EO on the growth of HeLa cell line. TO: Taraxacum officinale essential oil; DOX: standard doxorubicin (results are expressed as mean ± SD. (n = 5).
Bioactivities of the main constituents of the essential oil of the plant reported in the literature.
| Groups | Examples of Compounds Identified in Our Study | Bioactive Potential | Reference |
|---|---|---|---|
| Fatty acid | Anticancer, antioxidative, | [ | |
| Fatty alcohol | Antioxidative and anti-obesity | [ | |
| Diterpene monocyclic alcohol | Thunbergol | Anticancer, antiproliferative, anti-inflammatory, and cardioprotective | [ |